BMS ties with Janssen on Factor XIa inhibitor programme

Bristol-Myers Squibb and Janssen have announced a deal to work together on a Factor XIa (FXIa) inhibitor programme.

The collaboration will develop and commercialise blood thinner BMS-986177 for prevention and treatment of major thrombotic conditions.
Both Bristol Myers and Janssen intend to advance the blood thinner to mid- stage development and establish a inhibition development programme.

Tom Lynch, Executive Vice President and Chief Scientific officer at BMS commented, “By combining the strength of our companies’ extensive expertise in the development and commercialisation of cardiovascular treatments, we can maximise the potential of FXIa inhibition.”

The only financial details disclosed was that Janssen will pay BMS an upfront payment along with milestone payments, and the development costs and commercial profit and loss will be shared in due course.